Clinical activity of targeted antibodies, such as daratumumab (anti-CD38 antibody) and brentuximab vedotin (anti-CD30 antibody), have been reported in NKTCL. This evidence concerns the gene CD38 and extranodal nasal NK/T cell lymphoma.